Samantha MaWhinney
Concepts (510)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 87 | 2025 | 2821 | 4.590 |
Why?
| | Anti-HIV Agents | 40 | 2025 | 773 | 3.930 |
Why?
| | Adenine | 16 | 2025 | 268 | 2.100 |
Why?
| | Emtricitabine | 16 | 2025 | 175 | 2.070 |
Why?
| | Tenofovir | 18 | 2025 | 241 | 1.880 |
Why?
| | Organophosphates | 13 | 2025 | 134 | 1.820 |
Why?
| | Acquired Immunodeficiency Syndrome | 10 | 2023 | 232 | 1.590 |
Why?
| | HIV-1 | 31 | 2021 | 862 | 1.510 |
Why?
| | Dried Blood Spot Testing | 9 | 2024 | 103 | 1.440 |
Why?
| | Patient Dropouts | 3 | 2025 | 67 | 1.130 |
Why?
| | Pre-Exposure Prophylaxis | 8 | 2025 | 213 | 0.890 |
Why?
| | Medication Adherence | 12 | 2025 | 468 | 0.890 |
Why?
| | Viral Load | 20 | 2022 | 464 | 0.670 |
Why?
| | Directly Observed Therapy | 1 | 2017 | 15 | 0.570 |
Why?
| | Middle Aged | 68 | 2025 | 33225 | 0.520 |
Why?
| | Adult | 64 | 2025 | 37626 | 0.500 |
Why?
| | Anti-Retroviral Agents | 5 | 2019 | 232 | 0.490 |
Why?
| | Humans | 129 | 2025 | 136750 | 0.480 |
Why?
| | Leukocytes, Mononuclear | 9 | 2021 | 558 | 0.470 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 1036 | 0.470 |
Why?
| | Aging | 9 | 2023 | 1863 | 0.460 |
Why?
| | Male | 81 | 2025 | 67305 | 0.450 |
Why?
| | Zidovudine | 3 | 2012 | 78 | 0.430 |
Why?
| | Lamivudine | 3 | 2012 | 63 | 0.430 |
Why?
| | Female | 80 | 2025 | 72785 | 0.420 |
Why?
| | Unsafe Sex | 2 | 2012 | 59 | 0.420 |
Why?
| | Viremia | 6 | 2022 | 138 | 0.410 |
Why?
| | Cytochrome P-450 CYP3A | 2 | 2012 | 88 | 0.390 |
Why?
| | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 2 | 2025 | 19 | 0.390 |
Why?
| | CD8-Positive T-Lymphocytes | 9 | 2018 | 913 | 0.370 |
Why?
| | T-Lymphocytes, Cytotoxic | 6 | 2014 | 173 | 0.370 |
Why?
| | Sofosbuvir | 4 | 2022 | 59 | 0.370 |
Why?
| | Oligopeptides | 2 | 2012 | 271 | 0.360 |
Why?
| | Exercise | 6 | 2022 | 2044 | 0.350 |
Why?
| | Atazanavir Sulfate | 4 | 2016 | 41 | 0.350 |
Why?
| | Sustained Virologic Response | 3 | 2019 | 40 | 0.340 |
Why?
| | Models, Statistical | 5 | 2022 | 668 | 0.340 |
Why?
| | Prospective Studies | 23 | 2022 | 7572 | 0.340 |
Why?
| | HIV Integrase Inhibitors | 2 | 2024 | 70 | 0.330 |
Why?
| | Receptors, CCR5 | 6 | 2013 | 59 | 0.330 |
Why?
| | Dideoxynucleotides | 2 | 2012 | 14 | 0.320 |
Why?
| | Cytidine Triphosphate | 2 | 2012 | 16 | 0.320 |
Why?
| | CD4-Positive T-Lymphocytes | 9 | 2016 | 1095 | 0.320 |
Why?
| | Mobile Applications | 2 | 2022 | 182 | 0.320 |
Why?
| | Phosphorous Acids | 2 | 2019 | 12 | 0.320 |
Why?
| | Pyridines | 2 | 2012 | 506 | 0.320 |
Why?
| | Emigrants and Immigrants | 1 | 2012 | 138 | 0.310 |
Why?
| | Levonorgestrel | 2 | 2012 | 38 | 0.310 |
Why?
| | Antiviral Agents | 3 | 2019 | 738 | 0.300 |
Why?
| | Frailty | 2 | 2022 | 170 | 0.300 |
Why?
| | Sarcoma, Kaposi | 3 | 2022 | 81 | 0.290 |
Why?
| | Antiretroviral Therapy, Highly Active | 8 | 2019 | 271 | 0.290 |
Why?
| | Longitudinal Studies | 7 | 2025 | 2829 | 0.290 |
Why?
| | Quality of Life | 7 | 2023 | 2876 | 0.280 |
Why?
| | Gonadal Steroid Hormones | 1 | 2008 | 140 | 0.270 |
Why?
| | Lymphocyte Activation | 10 | 2018 | 1150 | 0.260 |
Why?
| | Exercise Therapy | 3 | 2020 | 436 | 0.260 |
Why?
| | Deoxyadenine Nucleotides | 2 | 2016 | 14 | 0.260 |
Why?
| | Prion Diseases | 1 | 2006 | 15 | 0.260 |
Why?
| | Deoxycytosine Nucleotides | 2 | 2016 | 11 | 0.260 |
Why?
| | Creutzfeldt-Jakob Syndrome | 1 | 2006 | 19 | 0.260 |
Why?
| | Wasting Disease, Chronic | 1 | 2006 | 26 | 0.260 |
Why?
| | Coronary Artery Bypass | 8 | 2004 | 233 | 0.250 |
Why?
| | Inflammation | 5 | 2021 | 2835 | 0.250 |
Why?
| | Lymph Nodes | 6 | 2017 | 492 | 0.250 |
Why?
| | Aged | 26 | 2023 | 23800 | 0.250 |
Why?
| | Data Interpretation, Statistical | 2 | 2025 | 363 | 0.250 |
Why?
| | Young Adult | 17 | 2025 | 13126 | 0.240 |
Why?
| | Gene Expression | 2 | 2014 | 1500 | 0.240 |
Why?
| | Simian Immunodeficiency Virus | 2 | 2016 | 88 | 0.230 |
Why?
| | CD4 Lymphocyte Count | 11 | 2020 | 268 | 0.230 |
Why?
| | Body Composition | 4 | 2024 | 678 | 0.230 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 2 | 2016 | 86 | 0.230 |
Why?
| | Bias | 2 | 2025 | 218 | 0.230 |
Why?
| | HIV | 4 | 2019 | 234 | 0.220 |
Why?
| | Contraceptives, Postcoital | 1 | 2004 | 2 | 0.220 |
Why?
| | Cross-Over Studies | 4 | 2020 | 562 | 0.220 |
Why?
| | Computer Simulation | 4 | 2025 | 973 | 0.220 |
Why?
| | Advance Care Planning | 2 | 2021 | 208 | 0.210 |
Why?
| | Population Surveillance | 3 | 2002 | 473 | 0.210 |
Why?
| | Cytokines | 3 | 2009 | 2084 | 0.210 |
Why?
| | Cohort Studies | 8 | 2023 | 5703 | 0.210 |
Why?
| | Physical Fitness | 2 | 2015 | 208 | 0.210 |
Why?
| | Lipopolysaccharide Receptors | 2 | 2021 | 85 | 0.210 |
Why?
| | HIV Integrase | 1 | 2024 | 70 | 0.200 |
Why?
| | Fluorenes | 2 | 2020 | 42 | 0.200 |
Why?
| | HIV Seropositivity | 3 | 2012 | 125 | 0.190 |
Why?
| | Drug Resistance, Viral | 2 | 2019 | 115 | 0.190 |
Why?
| | High-Intensity Interval Training | 1 | 2022 | 25 | 0.190 |
Why?
| | Telerehabilitation | 1 | 2022 | 37 | 0.190 |
Why?
| | Cell Phone | 1 | 2022 | 75 | 0.190 |
Why?
| | Lymphoid Tissue | 3 | 2008 | 75 | 0.190 |
Why?
| | RNA, Viral | 9 | 2014 | 654 | 0.190 |
Why?
| | Benzimidazoles | 2 | 2020 | 168 | 0.180 |
Why?
| | Hepatitis C | 2 | 2022 | 266 | 0.180 |
Why?
| | Alanine | 4 | 2024 | 151 | 0.180 |
Why?
| | Hair | 2 | 2018 | 84 | 0.180 |
Why?
| | Protease Inhibitors | 2 | 2020 | 106 | 0.180 |
Why?
| | Fees and Charges | 1 | 2000 | 10 | 0.170 |
Why?
| | Polyphosphates | 4 | 2022 | 36 | 0.170 |
Why?
| | Ritonavir | 2 | 2012 | 74 | 0.170 |
Why?
| | Hyperlipidemias | 1 | 2021 | 120 | 0.170 |
Why?
| | Advance Directives | 1 | 2021 | 72 | 0.160 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 116 | 0.160 |
Why?
| | Interleukin-10 | 2 | 2021 | 302 | 0.160 |
Why?
| | Costs and Cost Analysis | 1 | 2000 | 205 | 0.160 |
Why?
| | Research Design | 2 | 2025 | 1127 | 0.160 |
Why?
| | ADP-ribosyl Cyclase 1 | 4 | 2013 | 38 | 0.160 |
Why?
| | Thymine Nucleotides | 2 | 2016 | 16 | 0.150 |
Why?
| | Biomarkers | 7 | 2021 | 4145 | 0.150 |
Why?
| | Myocardial Ischemia | 1 | 2000 | 262 | 0.150 |
Why?
| | Cytomegalovirus Infections | 2 | 2015 | 191 | 0.150 |
Why?
| | Hepatitis C, Chronic | 2 | 2019 | 163 | 0.150 |
Why?
| | Blood Chemical Analysis | 4 | 2019 | 98 | 0.150 |
Why?
| | Colorado | 7 | 2022 | 4512 | 0.140 |
Why?
| | Simeprevir | 1 | 2018 | 9 | 0.140 |
Why?
| | Raltegravir Potassium | 2 | 2015 | 17 | 0.140 |
Why?
| | Transgender Persons | 1 | 2021 | 182 | 0.140 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2018 | 32 | 0.140 |
Why?
| | Virus Replication | 5 | 2017 | 482 | 0.140 |
Why?
| | Epitopes, T-Lymphocyte | 4 | 2008 | 187 | 0.140 |
Why?
| | Viral Tropism | 1 | 2017 | 31 | 0.140 |
Why?
| | Sleep Wake Disorders | 1 | 2020 | 283 | 0.130 |
Why?
| | Pharmacogenetics | 2 | 2016 | 179 | 0.130 |
Why?
| | AIDS-Related Opportunistic Infections | 3 | 2007 | 126 | 0.130 |
Why?
| | Length of Stay | 4 | 2000 | 1204 | 0.130 |
Why?
| | Pyrophosphatases | 1 | 2016 | 28 | 0.130 |
Why?
| | Deoxyguanine Nucleotides | 1 | 2016 | 11 | 0.130 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2017 | 137 | 0.130 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 443 | 0.130 |
Why?
| | Genitalia | 1 | 2016 | 30 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2019 | 503 | 0.130 |
Why?
| | Germinal Center | 1 | 2016 | 58 | 0.130 |
Why?
| | Motor Activity | 4 | 2015 | 717 | 0.130 |
Why?
| | Vaccines, DNA | 2 | 2008 | 32 | 0.130 |
Why?
| | Ribavirin | 1 | 2016 | 91 | 0.120 |
Why?
| | HIV Protease Inhibitors | 2 | 2016 | 69 | 0.120 |
Why?
| | AIDS Vaccines | 2 | 2008 | 52 | 0.120 |
Why?
| | Purines | 1 | 2016 | 176 | 0.120 |
Why?
| | Muscle Strength | 1 | 2018 | 315 | 0.120 |
Why?
| | Risk Factors | 11 | 2021 | 10330 | 0.120 |
Why?
| | Disease Transmission, Infectious | 2 | 2018 | 62 | 0.120 |
Why?
| | Biometry | 2 | 2011 | 70 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 4 | 2015 | 425 | 0.120 |
Why?
| | HLA-DR Antigens | 3 | 2012 | 228 | 0.120 |
Why?
| | Case-Control Studies | 7 | 2016 | 3540 | 0.120 |
Why?
| | Genitalia, Female | 1 | 2015 | 38 | 0.120 |
Why?
| | Rectum | 1 | 2016 | 185 | 0.120 |
Why?
| | Antibodies, Viral | 3 | 2015 | 623 | 0.110 |
Why?
| | Mental Health Services | 1 | 2019 | 416 | 0.110 |
Why?
| | Organophosphonates | 1 | 2015 | 93 | 0.110 |
Why?
| | Linear Models | 4 | 2020 | 845 | 0.110 |
Why?
| | Probability | 2 | 2011 | 304 | 0.110 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2017 | 387 | 0.110 |
Why?
| | Calcifediol | 1 | 2014 | 33 | 0.110 |
Why?
| | Sexual and Gender Minorities | 1 | 2017 | 213 | 0.110 |
Why?
| | Deoxycytidine | 1 | 2015 | 179 | 0.110 |
Why?
| | Calcitriol | 1 | 2014 | 58 | 0.110 |
Why?
| | Immunoglobulin Variable Region | 1 | 2014 | 80 | 0.110 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2014 | 81 | 0.110 |
Why?
| | Membrane Glycoproteins | 3 | 2013 | 500 | 0.110 |
Why?
| | Telemedicine | 1 | 2022 | 852 | 0.110 |
Why?
| | Disease Progression | 4 | 2015 | 2751 | 0.110 |
Why?
| | Patient Compliance | 1 | 2017 | 577 | 0.100 |
Why?
| | Decision Making | 1 | 2021 | 898 | 0.100 |
Why?
| | Multivariate Analysis | 8 | 2007 | 1507 | 0.100 |
Why?
| | Adolescent | 14 | 2020 | 21380 | 0.100 |
Why?
| | Gastrointestinal Microbiome | 1 | 2021 | 698 | 0.100 |
Why?
| | Chromatography, Liquid | 3 | 2019 | 432 | 0.100 |
Why?
| | Microbiota | 1 | 2021 | 762 | 0.100 |
Why?
| | Immunoglobulin G | 2 | 2015 | 887 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2015 | 236 | 0.100 |
Why?
| | Time Factors | 8 | 2019 | 6808 | 0.100 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 1994 | 182 | 0.100 |
Why?
| | Spleen | 1 | 2014 | 514 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2004 | 2047 | 0.100 |
Why?
| | Hepatitis A Vaccines | 1 | 2012 | 15 | 0.100 |
Why?
| | Dendritic Cells | 2 | 2008 | 484 | 0.100 |
Why?
| | Hepatitis A | 1 | 2012 | 26 | 0.100 |
Why?
| | Benzoxazines | 1 | 2012 | 31 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1033 | 0.090 |
Why?
| | Numerical Analysis, Computer-Assisted | 2 | 2002 | 19 | 0.090 |
Why?
| | Cervix Uteri | 1 | 2012 | 48 | 0.090 |
Why?
| | Tandem Mass Spectrometry | 3 | 2019 | 531 | 0.090 |
Why?
| | Sarcopenia | 1 | 2013 | 82 | 0.090 |
Why?
| | Cell Movement | 3 | 2016 | 968 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 249 | 0.090 |
Why?
| | Contraceptive Agents | 1 | 2012 | 66 | 0.090 |
Why?
| | Haplotypes | 2 | 2012 | 494 | 0.090 |
Why?
| | Benchmarking | 2 | 2024 | 183 | 0.090 |
Why?
| | Muscle, Skeletal | 1 | 2021 | 1707 | 0.090 |
Why?
| | B-Lymphocytes | 1 | 2016 | 846 | 0.090 |
Why?
| | Polymorphism, Genetic | 2 | 2016 | 659 | 0.090 |
Why?
| | CD4 Antigens | 1 | 2011 | 142 | 0.090 |
Why?
| | Retrospective Studies | 9 | 2021 | 15499 | 0.090 |
Why?
| | Mental Disorders | 1 | 2019 | 1070 | 0.090 |
Why?
| | Contraceptive Agents, Female | 1 | 2012 | 80 | 0.090 |
Why?
| | Sex Factors | 5 | 2018 | 2064 | 0.090 |
Why?
| | HIV Seronegativity | 1 | 2010 | 28 | 0.090 |
Why?
| | Antacids | 1 | 2010 | 16 | 0.090 |
Why?
| | Pyrrolidinones | 1 | 2010 | 28 | 0.090 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1904 | 0.090 |
Why?
| | Drug Monitoring | 2 | 2022 | 218 | 0.090 |
Why?
| | Osteoporosis | 1 | 2013 | 243 | 0.080 |
Why?
| | Accidental Falls | 1 | 2012 | 193 | 0.080 |
Why?
| | Herpesvirus 8, Human | 2 | 2000 | 65 | 0.080 |
Why?
| | Postmenopause | 1 | 2012 | 365 | 0.080 |
Why?
| | Cross-Sectional Studies | 8 | 2019 | 5419 | 0.080 |
Why?
| | Diphosphates | 2 | 2021 | 17 | 0.080 |
Why?
| | Predictive Value of Tests | 4 | 2019 | 2021 | 0.080 |
Why?
| | Cytomegalovirus | 2 | 2015 | 157 | 0.080 |
Why?
| | Zimbabwe | 3 | 2022 | 55 | 0.080 |
Why?
| | Drug Interactions | 3 | 2019 | 406 | 0.080 |
Why?
| | Complementarity Determining Regions | 2 | 2014 | 51 | 0.080 |
Why?
| | Cytotoxicity Tests, Immunologic | 3 | 2003 | 41 | 0.070 |
Why?
| | Molecular Sequence Data | 3 | 2009 | 2894 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2016 | 2184 | 0.070 |
Why?
| | Demography | 2 | 2022 | 291 | 0.070 |
Why?
| | Sequence Analysis, DNA | 2 | 2009 | 809 | 0.070 |
Why?
| | Lung Diseases | 1 | 2015 | 768 | 0.070 |
Why?
| | Hepacivirus | 2 | 2022 | 260 | 0.070 |
Why?
| | Mutation | 2 | 2014 | 3947 | 0.070 |
Why?
| | Healthy Volunteers | 2 | 2018 | 199 | 0.070 |
Why?
| | Plasma | 1 | 2009 | 213 | 0.070 |
Why?
| | Interleukin-12 | 2 | 1998 | 121 | 0.070 |
Why?
| | Hospitals, Veterans | 3 | 2004 | 249 | 0.070 |
Why?
| | Managed Care Programs | 1 | 2007 | 130 | 0.060 |
Why?
| | Deer | 1 | 2006 | 32 | 0.060 |
Why?
| | Adipocytes | 1 | 2008 | 222 | 0.060 |
Why?
| | Interferon-gamma | 3 | 2008 | 789 | 0.060 |
Why?
| | Comorbidity | 3 | 2019 | 1614 | 0.060 |
Why?
| | Therapeutic Equivalency | 2 | 2018 | 32 | 0.060 |
Why?
| | Treatment Outcome | 10 | 2018 | 10747 | 0.060 |
Why?
| | Self Report | 2 | 2021 | 822 | 0.060 |
Why?
| | Physicians, Family | 1 | 2007 | 201 | 0.060 |
Why?
| | Preventive Health Services | 1 | 2007 | 148 | 0.060 |
Why?
| | Interleukin-6 | 2 | 2021 | 778 | 0.060 |
Why?
| | Kenya | 1 | 2025 | 115 | 0.060 |
Why?
| | Macaca mulatta | 2 | 2016 | 166 | 0.060 |
Why?
| | Flow Cytometry | 4 | 2015 | 1180 | 0.060 |
Why?
| | Immunoenzyme Techniques | 1 | 2005 | 219 | 0.060 |
Why?
| | Incidence | 4 | 2012 | 2797 | 0.060 |
Why?
| | T-Lymphocytes | 3 | 2005 | 1993 | 0.060 |
Why?
| | Area Under Curve | 2 | 2018 | 314 | 0.060 |
Why?
| | Licensure, Pharmacy | 1 | 2004 | 1 | 0.060 |
Why?
| | Northern Ireland | 1 | 2004 | 7 | 0.060 |
Why?
| | Immunologic Memory | 2 | 2009 | 370 | 0.050 |
Why?
| | New York City | 2 | 1994 | 85 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2016 | 250 | 0.050 |
Why?
| | Pilot Projects | 3 | 2022 | 1693 | 0.050 |
Why?
| | Odds Ratio | 3 | 2014 | 1065 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 3 | 2015 | 388 | 0.050 |
Why?
| | Hospitalization | 3 | 2022 | 2181 | 0.050 |
Why?
| | Survival Analysis | 3 | 2015 | 1321 | 0.050 |
Why?
| | HIV Antibodies | 2 | 2014 | 62 | 0.050 |
Why?
| | Conserved Sequence | 1 | 2003 | 239 | 0.050 |
Why?
| | Ki-67 Antigen | 2 | 2017 | 111 | 0.050 |
Why?
| | Patient Satisfaction | 1 | 2007 | 656 | 0.050 |
Why?
| | Integrases | 1 | 2024 | 120 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2014 | 5739 | 0.050 |
Why?
| | Tablets | 1 | 2022 | 40 | 0.050 |
Why?
| | Quality of Health Care | 1 | 2007 | 633 | 0.050 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2002 | 84 | 0.050 |
Why?
| | Creatinine | 3 | 2018 | 498 | 0.050 |
Why?
| | Likelihood Functions | 3 | 2001 | 143 | 0.050 |
Why?
| | Cells, Cultured | 4 | 2017 | 4192 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 1062 | 0.050 |
Why?
| | Models, Biological | 2 | 2016 | 1773 | 0.050 |
Why?
| | Drug Prescriptions | 1 | 2004 | 244 | 0.050 |
Why?
| | Bayes Theorem | 2 | 2020 | 404 | 0.050 |
Why?
| | Habits | 1 | 2022 | 49 | 0.050 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2021 | 10 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2007 | 763 | 0.050 |
Why?
| | Angina Pectoris | 1 | 2001 | 65 | 0.050 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2021 | 42 | 0.050 |
Why?
| | Citrate (si)-Synthase | 1 | 2021 | 60 | 0.050 |
Why?
| | Phenotype | 4 | 2016 | 3189 | 0.050 |
Why?
| | Antigens, Viral | 3 | 2014 | 181 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 42 | 0.040 |
Why?
| | Mental Health | 2 | 2019 | 716 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 87 | 0.040 |
Why?
| | Diagnosis-Related Groups | 1 | 2000 | 30 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 337 | 0.040 |
Why?
| | Hand Strength | 1 | 2021 | 122 | 0.040 |
Why?
| | Hemarthrosis | 1 | 2000 | 21 | 0.040 |
Why?
| | HIV Antigens | 2 | 2015 | 18 | 0.040 |
Why?
| | Actigraphy | 1 | 2020 | 110 | 0.040 |
Why?
| | Heart Valves | 1 | 2000 | 43 | 0.040 |
Why?
| | Weight Gain | 1 | 2024 | 519 | 0.040 |
Why?
| | Death | 1 | 2021 | 119 | 0.040 |
Why?
| | Weight Loss | 2 | 2020 | 776 | 0.040 |
Why?
| | Communicable Diseases | 1 | 2002 | 159 | 0.040 |
Why?
| | Virus Diseases | 1 | 2002 | 213 | 0.040 |
Why?
| | Immunophenotyping | 3 | 2007 | 319 | 0.040 |
Why?
| | Drug Combinations | 1 | 2020 | 343 | 0.040 |
Why?
| | Amino Acid Motifs | 2 | 2014 | 225 | 0.040 |
Why?
| | Superoxide Dismutase | 1 | 2021 | 346 | 0.040 |
Why?
| | Sickness Impact Profile | 1 | 1999 | 56 | 0.040 |
Why?
| | Age Factors | 3 | 2000 | 3286 | 0.040 |
Why?
| | Regression Analysis | 2 | 2007 | 1022 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 487 | 0.040 |
Why?
| | Capsules | 1 | 2018 | 38 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2007 | 225 | 0.040 |
Why?
| | Herpesviridae Infections | 1 | 1999 | 149 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2022 | 949 | 0.040 |
Why?
| | Uganda | 1 | 2018 | 73 | 0.040 |
Why?
| | Renal Insufficiency | 1 | 2000 | 155 | 0.040 |
Why?
| | Chemoprevention | 1 | 2018 | 92 | 0.040 |
Why?
| | Drug Compounding | 1 | 2018 | 101 | 0.040 |
Why?
| | Chemistry Techniques, Analytical | 1 | 2018 | 21 | 0.040 |
Why?
| | Nanomedicine | 1 | 2018 | 47 | 0.040 |
Why?
| | Hemophilia A | 1 | 2000 | 139 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 115 | 0.040 |
Why?
| | Oxazines | 1 | 2018 | 30 | 0.040 |
Why?
| | Fluconazole | 1 | 1997 | 19 | 0.040 |
Why?
| | Histoplasmosis | 1 | 1997 | 17 | 0.040 |
Why?
| | Heart Diseases | 2 | 2000 | 346 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2022 | 417 | 0.030 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2018 | 82 | 0.030 |
Why?
| | Severity of Illness Index | 3 | 2000 | 2819 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2021 | 7593 | 0.030 |
Why?
| | Cardiology Service, Hospital | 1 | 1997 | 24 | 0.030 |
Why?
| | Adaptation, Physiological | 1 | 2021 | 549 | 0.030 |
Why?
| | Internet | 1 | 2002 | 647 | 0.030 |
Why?
| | Cause of Death | 1 | 2019 | 429 | 0.030 |
Why?
| | Palatine Tonsil | 1 | 2017 | 48 | 0.030 |
Why?
| | Inosine Triphosphate | 1 | 2016 | 2 | 0.030 |
Why?
| | Fatigue | 1 | 2019 | 326 | 0.030 |
Why?
| | Anemia, Hemolytic | 1 | 2016 | 20 | 0.030 |
Why?
| | Perforin | 1 | 2016 | 19 | 0.030 |
Why?
| | Clinical Studies as Topic | 1 | 2016 | 10 | 0.030 |
Why?
| | Genotype | 3 | 2012 | 1914 | 0.030 |
Why?
| | Antifungal Agents | 1 | 1997 | 136 | 0.030 |
Why?
| | Guanosine Triphosphate | 1 | 2016 | 91 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2000 | 574 | 0.030 |
Why?
| | Primary Health Care | 1 | 2007 | 1722 | 0.030 |
Why?
| | Half-Life | 1 | 2016 | 164 | 0.030 |
Why?
| | Child | 7 | 2017 | 21816 | 0.030 |
Why?
| | Lymphocyte Depletion | 1 | 2016 | 135 | 0.030 |
Why?
| | Machine Learning | 1 | 2021 | 488 | 0.030 |
Why?
| | Pyridones | 1 | 2018 | 168 | 0.030 |
Why?
| | Prognosis | 2 | 2021 | 4012 | 0.030 |
Why?
| | Lung | 2 | 2022 | 4061 | 0.030 |
Why?
| | Eating | 1 | 1999 | 379 | 0.030 |
Why?
| | Peru | 1 | 2016 | 58 | 0.030 |
Why?
| | Nucleotides | 1 | 2016 | 124 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 431 | 0.030 |
Why?
| | United States | 6 | 2016 | 14682 | 0.030 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 1998 | 180 | 0.030 |
Why?
| | Spermatozoa | 1 | 2016 | 94 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2016 | 190 | 0.030 |
Why?
| | Clinical Protocols | 1 | 1997 | 267 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1462 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1242 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 1998 | 257 | 0.030 |
Why?
| | Algorithms | 2 | 2011 | 1688 | 0.030 |
Why?
| | Human Activities | 1 | 2015 | 21 | 0.030 |
Why?
| | Piperazines | 1 | 2018 | 350 | 0.030 |
Why?
| | South Africa | 1 | 2016 | 219 | 0.030 |
Why?
| | Animals | 4 | 2016 | 36836 | 0.030 |
Why?
| | Receptors, CXCR4 | 2 | 2007 | 86 | 0.030 |
Why?
| | Drug Users | 1 | 2015 | 40 | 0.030 |
Why?
| | Receptors, CXCR5 | 1 | 2014 | 21 | 0.030 |
Why?
| | Receptors, CCR7 | 1 | 2014 | 32 | 0.030 |
Why?
| | Blood | 1 | 2015 | 106 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 729 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 785 | 0.030 |
Why?
| | Cathelicidins | 1 | 2014 | 41 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2016 | 487 | 0.030 |
Why?
| | Registries | 1 | 2022 | 2014 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2012 | 1059 | 0.030 |
Why?
| | Mutation Rate | 1 | 2014 | 29 | 0.030 |
Why?
| | Child, Preschool | 4 | 2002 | 10997 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 1 | 2015 | 114 | 0.030 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2014 | 93 | 0.030 |
Why?
| | Aging, Premature | 1 | 2013 | 13 | 0.030 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 39 | 0.030 |
Why?
| | Body Fat Distribution | 1 | 2013 | 49 | 0.030 |
Why?
| | Kidney Failure, Chronic | 1 | 1999 | 566 | 0.030 |
Why?
| | Infant | 3 | 2002 | 9395 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2014 | 306 | 0.020 |
Why?
| | Energy Metabolism | 1 | 1999 | 919 | 0.020 |
Why?
| | Mothers | 1 | 1999 | 752 | 0.020 |
Why?
| | Infant, Newborn | 2 | 1994 | 6031 | 0.020 |
Why?
| | Frail Elderly | 1 | 2013 | 132 | 0.020 |
Why?
| | Muscles | 1 | 2013 | 325 | 0.020 |
Why?
| | Clone Cells | 2 | 2002 | 266 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2015 | 654 | 0.020 |
Why?
| | Cyclopropanes | 1 | 2012 | 90 | 0.020 |
Why?
| | Alkynes | 1 | 2012 | 56 | 0.020 |
Why?
| | Receptors, HIV | 1 | 2011 | 24 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 328 | 0.020 |
Why?
| | Cardiac Surgical Procedures | 1 | 1997 | 530 | 0.020 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2013 | 316 | 0.020 |
Why?
| | Bone and Bones | 1 | 2013 | 316 | 0.020 |
Why?
| | Geography | 1 | 2011 | 198 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2015 | 5105 | 0.020 |
Why?
| | Pregnancy Complications, Infectious | 1 | 1994 | 389 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2016 | 1094 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2012 | 345 | 0.020 |
Why?
| | Chi-Square Distribution | 2 | 2002 | 530 | 0.020 |
Why?
| | Depression | 1 | 2019 | 1397 | 0.020 |
Why?
| | North America | 1 | 2011 | 311 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2001 | 2639 | 0.020 |
Why?
| | Interleukin-2 | 2 | 2003 | 455 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2012 | 587 | 0.020 |
Why?
| | Bone Density | 1 | 2013 | 487 | 0.020 |
Why?
| | Body Mass Index | 2 | 2013 | 2373 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2016 | 2476 | 0.020 |
Why?
| | Postoperative Hemorrhage | 2 | 2000 | 86 | 0.020 |
Why?
| | United States Department of Veterans Affairs | 2 | 2004 | 674 | 0.020 |
Why?
| | DNA, Viral | 2 | 2000 | 363 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2000 | 3556 | 0.020 |
Why?
| | Respiratory Tract Diseases | 2 | 2000 | 184 | 0.020 |
Why?
| | Health Status | 2 | 2004 | 788 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 1282 | 0.020 |
Why?
| | Personnel Turnover | 1 | 2007 | 40 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2605 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 514 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2007 | 150 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 889 | 0.020 |
Why?
| | Sweating | 1 | 2007 | 40 | 0.020 |
Why?
| | Risk Assessment | 3 | 2004 | 3432 | 0.020 |
Why?
| | Hospital Mortality | 2 | 2004 | 901 | 0.020 |
Why?
| | Gender Identity | 1 | 2007 | 124 | 0.020 |
Why?
| | Fever | 1 | 2007 | 306 | 0.010 |
Why?
| | Health Care Surveys | 1 | 2007 | 562 | 0.010 |
Why?
| | Obesity | 1 | 1999 | 2982 | 0.010 |
Why?
| | Selection Bias | 1 | 2005 | 37 | 0.010 |
Why?
| | DNA | 1 | 2012 | 1458 | 0.010 |
Why?
| | Quality Indicators, Health Care | 1 | 2007 | 307 | 0.010 |
Why?
| | Acute Disease | 1 | 2007 | 1007 | 0.010 |
Why?
| | Neoplasms | 1 | 2019 | 2643 | 0.010 |
Why?
| | Base Sequence | 1 | 2008 | 2179 | 0.010 |
Why?
| | Cell Line | 2 | 2001 | 2838 | 0.010 |
Why?
| | HLA-A3 Antigen | 1 | 2003 | 6 | 0.010 |
Why?
| | HLA-B7 Antigen | 1 | 2003 | 7 | 0.010 |
Why?
| | HLA-A2 Antigen | 1 | 2003 | 48 | 0.010 |
Why?
| | Superantigens | 1 | 2003 | 70 | 0.010 |
Why?
| | Intraoperative Care | 1 | 2004 | 49 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 2003 | 126 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 2003 | 145 | 0.010 |
Why?
| | Virus Activation | 1 | 2003 | 88 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2008 | 1982 | 0.010 |
Why?
| | B7-2 Antigen | 1 | 2002 | 27 | 0.010 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2003 | 184 | 0.010 |
Why?
| | Postoperative Period | 1 | 2004 | 343 | 0.010 |
Why?
| | Chronic Disease | 1 | 2009 | 1786 | 0.010 |
Why?
| | Morbidity | 1 | 2004 | 322 | 0.010 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2002 | 22 | 0.010 |
Why?
| | Parainfluenza Virus 3, Human | 1 | 2002 | 5 | 0.010 |
Why?
| | Community Medicine | 1 | 2002 | 6 | 0.010 |
Why?
| | Hospital-Physician Relations | 1 | 2002 | 4 | 0.010 |
Why?
| | Rotavirus | 1 | 2002 | 20 | 0.010 |
Why?
| | CD40 Antigens | 1 | 2002 | 89 | 0.010 |
Why?
| | Attitude to Computers | 1 | 2002 | 29 | 0.010 |
Why?
| | Sick Role | 1 | 2001 | 18 | 0.010 |
Why?
| | HIV Core Protein p24 | 1 | 2001 | 31 | 0.010 |
Why?
| | Immunity, Cellular | 1 | 2003 | 268 | 0.010 |
Why?
| | Streptococcus pyogenes | 1 | 2002 | 45 | 0.010 |
Why?
| | Pregnancy | 1 | 1994 | 6727 | 0.010 |
Why?
| | Preoperative Care | 1 | 2004 | 356 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 851 | 0.010 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2002 | 74 | 0.010 |
Why?
| | Health Services Research | 1 | 2004 | 400 | 0.010 |
Why?
| | Nonlinear Dynamics | 1 | 2001 | 88 | 0.010 |
Why?
| | Phosphorus Radioisotopes | 1 | 2000 | 30 | 0.010 |
Why?
| | Elbow | 1 | 2000 | 55 | 0.010 |
Why?
| | Community-Acquired Infections | 1 | 2002 | 169 | 0.010 |
Why?
| | Ankle | 1 | 2000 | 60 | 0.010 |
Why?
| | Antigens, CD | 1 | 2002 | 521 | 0.010 |
Why?
| | Knee | 1 | 2000 | 68 | 0.010 |
Why?
| | Hyperplasia | 1 | 2000 | 175 | 0.010 |
Why?
| | Hemophilia B | 1 | 2000 | 61 | 0.010 |
Why?
| | Forecasting | 1 | 2001 | 388 | 0.010 |
Why?
| | Synovial Membrane | 1 | 2000 | 117 | 0.010 |
Why?
| | Seasons | 1 | 2002 | 544 | 0.010 |
Why?
| | Calorimetry, Indirect | 1 | 1999 | 84 | 0.010 |
Why?
| | Diet Records | 1 | 1999 | 83 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1998 | 50 | 0.010 |
Why?
| | Fathers | 1 | 1999 | 50 | 0.010 |
Why?
| | Cost Control | 1 | 1998 | 39 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2003 | 2163 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2138 | 0.010 |
Why?
| | Anthropometry | 1 | 1999 | 213 | 0.010 |
Why?
| | Activities of Daily Living | 1 | 2001 | 414 | 0.010 |
Why?
| | Erythrocyte Transfusion | 1 | 2000 | 193 | 0.010 |
Why?
| | Absorptiometry, Photon | 1 | 1999 | 254 | 0.010 |
Why?
| | Radiography | 1 | 2000 | 822 | 0.010 |
Why?
| | Puberty | 1 | 1999 | 146 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2000 | 1316 | 0.010 |
Why?
| | Streptokinase | 1 | 1996 | 10 | 0.010 |
Why?
| | Phytohemagglutinins | 1 | 1996 | 30 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2005 | 3264 | 0.010 |
Why?
| | Tetanus Toxoid | 1 | 1996 | 35 | 0.010 |
Why?
| | Candida | 1 | 1996 | 36 | 0.010 |
Why?
| | Cell Division | 1 | 1998 | 796 | 0.010 |
Why?
| | Postoperative Care | 1 | 1998 | 261 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 1997 | 686 | 0.010 |
Why?
| | Antigens, Bacterial | 1 | 1996 | 129 | 0.010 |
Why?
| | Exercise Test | 1 | 1999 | 625 | 0.010 |
Why?
| | Survival Rate | 1 | 2000 | 1962 | 0.010 |
Why?
| | Logistic Models | 1 | 2000 | 2067 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 1999 | 712 | 0.010 |
Why?
| | Adipose Tissue | 1 | 1999 | 630 | 0.010 |
Why?
| | Patient Selection | 1 | 1997 | 691 | 0.010 |
Why?
| | Databases, Factual | 1 | 1999 | 1351 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1350 | 0.010 |
Why?
| | Prevalence | 1 | 1999 | 2708 | 0.010 |
Why?
| | Mice | 1 | 2003 | 17758 | 0.000 |
Why?
|
|
MaWhinney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|